Session Information
2008 Midyear Clinical Meeting
Click here to go to the previous page
Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Track:
Educational Sessions
Program Code: 280-L01
Date: Wednesday, December 10, 2008
Time: 4:00 PM to 5:00 PM EST
Location:
S230D
MEETING PLANNING ASSOCIATE:
Dr. Cynthia LaCivita, PharmD, Director, Education and Special Programs, ASHP Research & Education Foundation
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
Click the plus sign to see more detailed information about each speaker.
Dr. Cynthia LaCivita, PharmD, Director, Education and Special Programs, ASHP Research & Education Foundation
- Identify the appropriate screening and monitoring parameters for tuberculosis in the setting of anticipated or ongoing biologic disease-modifying antirheumatic drug therapy.
- Identify the therapeutic indications for biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
- Identify the therapeutic indications for combination therapy with nonbiologics (e.g., methotrexate and sulfasalazine; methotrexate and hydroxychloroquine, methotrexate plus leflunomide) in patients with rheumatoid arthritis.
- List the contra-indications to starting or resuming biologic disease-modifying antirheumatic therapy in the context of safety, monitoring and risk surveillance.